DrugCard

DrugCard is a pharmacovigilance software company that develops AI-driven tools and services for automated literature monitoring, adverse event management, and regulatory intelligence. Founded in 2019 by brothers Artem and Dmytro Horilyk alongside Myroslav Demchun, the platform was built to replace manual literature screening processes with automated, AI-assisted workflows. DrugCard serves contract research organisations (CROs), marketing authorisation holders (MAHs), and freelance pharmacovigilance specialists operating across global and local markets.

As of 2025, DrugCard operates across 121+ countries, monitors more than 2,200 local medical journals, supports over 100 languages, and processes more than one million articles. The platform reports time savings of 50–70% compared to manual-only approaches, with individual article review reduced from approximately 35 minutes to under 3 minutes according to customer feedback.

Core Platform Capabilities

• Automated literature screening across local and global medical journals in 100+ languages
• Coverage of 2,200+ continuously monitored local journals spanning 121+ countries
• Proprietary OCR technology delivering up to 99% accuracy on average-quality scanned texts, including poorly scanned hard copies
• LLM-based article categorisation for automated relevance assessment
• AI Case Intake module, released in December 2024, which automatically extracts adverse reaction data from unstructured text
• AI-based global literature assessment and regulatory intelligence
• Safety database solutions

Products and Modules

• Automated Literature Monitoring: Continuous screening of local and global medical journals for drug safety signals, replacing manual cover-to-cover reading
• AI Case Intake: Automated extraction of individual case safety report (ICSR) data from unstructured article text
• Regulatory Intelligence: Monitoring and tracking of regulatory requirements across multiple markets and regions
• PV Services: Managed pharmacovigilance services delivered by an in-house team of specialists, covering literature monitoring, ICSR preparation, PV audit support, and SOP development; as of 2025, the service covers 11 projects across 21 countries

Target Users

• CROs: Enables contract research organisations to manage a higher volume of pharmacovigilance projects and improve screening completeness without relying solely on manual reading
• MAHs: Supports marketing authorisation holders in conducting literature screening in-house at both global and local levels, reducing dependence on multiple external CRO contractors and associated compliance risks
• Freelancers: Allows independent pharmacovigilance specialists to reduce time spent on literature review by up to 70%, freeing capacity for consulting, signal detection, PSUR preparation, and quality assurance

Key Platform Characteristics

• Multi-language and multi-region coverage supporting scalability into new markets
• Designed to meet GVP regulatory requirements with traceable and transparent screening records
• Continuous and regular monitoring rather than periodic manual reviews
• CAPEX-free subscription model
• Scalable architecture overseen by a dedicated CTO function focused on reliability and security

Company History and Growth

• 2019: Concept originated from a discussion between Artem Horilyk, then working as a pharmacovigilance specialist, and his brother Dmytro about automating manual screening
• 2020: MVP completed by August; client outreach began
• 2021: First client signed in April; first investment received from Spain and Ukraine in December
• 2022: Expanded to Europe and the UK, with first German clients onboarded
• 2023: AI model training on real pharmacovigilance data began; PV services launched; reached 10 clients across 30 countries with a team of 10
• 2024: LLM model introduced; AI Case Intake released; presented at the DIA conference in Brussels; grew to 22 team members and 48 clients across 55 countries
• 2025: Expanded to 121+ countries; team and service portfolio continued to grow

DrugCard's stated mission is to develop artificial intelligence that performs pharmacovigilance functions, converting unstructured data into actionable safety insights and automating article analysis and reporting so that pharmacovigilance professionals can concentrate on signal detection, regulatory submissions, and patient safety decisions.